CEL-SCI Corporation (CVM)
0.40
-0.01 (-3.59%)
At close: Jan 14, 2025, 3:59 PM
0.39
-2.43%
Pre-market Jan 15, 2025, 05:53 AM EST
undefined% (undefined)
| Bid | 0.39 |
| Market Cap | 29.78M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.58 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.4 |
| Volume | 247,757 |
| Avg. Volume (20D) | 984,362 |
| Open | 0.40 |
| Previous Close | 0.41 |
| Day's Range | 0.40 - 0.41 |
| 52-Week Range | 0.36 - 3.08 |
| Beta | undefined |
About CVM
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, a...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 1983
Employees 43
Stock Exchange AMEX
Ticker Symbol CVM
Website https://cel-sci.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CVM stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 weeks ago ·
Source
-32.26%
Cel-Sci shares are trading lower after the company...
Unlock content with
Pro Subscription
11 months ago ·
Source
-13.68%
Cel-Sci shares are trading lower after the company announced pricing of a $7.75 million public offering of 3.875 million shares of common stock at $2 per share.
